Clinical Research
Filter News
Found 135,798 articles
-
Two researchers affiliated with Northwestern University have discovered a new drug that may outperform existing treatments for amyotrophic lateral sclerosis (ALS).
-
Researchers at the University of California, Los Angeles have identified a neurological mechanism behind memory linking.
-
Today, scientist-founders are likely to remain in charge, shepherding the companies they founded to the next iteration. BioSpace spoke with one such founder, Mammoth Biosciences' Trevor Martin.
-
Warnings of Monkeypox went unheeded as scientists around the world began to uncover clues about the disease's origin. Here are the latest updates on the monkeypox virus.
-
Four biotech companies are holding Research-and-Development Day events to present and discuss their pipelines. Here’s a look.
-
A recent study published in Nature Medicine found that people who were vaccinated had a slightly decreased risk of getting Long COVID six months after their initial diagnosis.
-
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors- EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic -
5/26/2022
CytomX Therapeutics, Inc. today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 ( NCT05387265 ).
-
Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples
5/26/2022
Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”) , a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that it has received European CE mark designation for its eLab S1 assay panel for use with a lithium heparinized whole blood sample.
-
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
5/26/2022
SciSparc Ltd. today announced it received Ethics Committee approvals from Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel, to conduct the Company’s Phase IIb clinical study for SCI-110 in patients suffering from Tourette Syndrome ("TS").
-
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer
5/26/2022
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced top-line clinical data from its Phase 1/2 trial of galinpepimut-S.
-
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
5/26/2022
Laekna Therapeutics, a clinical-stage biotechnology company developing innovative medicines to treat cancer and liver diseases, today announced that two first patients have been dosed in the U.S. and China, respectively, in a Phase Ib/III clinical trial that evaluates the efficacy and safety of afuresertib.
-
US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD
5/26/2022
US FDA has cleared Cynata's IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company.
-
Devonian Health Group Announces the Journal of Drugs in Dermatology Acceptance for Publication of Thykamine™ Positive Phase 2 Clinical Trial Results in Atopic Dermatitis
5/26/2022
Devonian Health Group Inc. today announced the acceptance for publication of results from its positive phase 2 trial of Thykamine™ in patients with mild-to-moderate Atopic Dermatitis.
-
Neuvivo Closes on Additional Funding Round for NP001 Development
5/26/2022
Neuvivo, a late-clinical stage biopharmaceutical company developing a new ALS treatment, today announced that it has closed on an additional round of financing led by an international investment group.
-
Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
5/26/2022
Moleculin Biotech, Inc. today announced the commencement of dosing in its first-in-human Phase 1a study to evaluate the safety and pharmacokinetics (PK) of WP1122 in healthy volunteers for the treatment of COVID-19 (MB-301).
-
Strata Oncology Expands Strata PATH Trial with Two New Partners
5/26/2022
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that two new health system partners.
-
Yingli Pharma Doses First US Patient in Phase 1 Study of YL-13027 for Patients with Advanced Solid Tumors
5/26/2022
Yingli Pharma US, Inc, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating YL-13027 a potent and selective TGFβ receptor 1 (TGFβR1) inhibitor.
-
SinuSonic Announces Presentation of Double-Blind, Sham-Controlled Trial Data Showing Regular Use of the Device Improved Nasal Congestion
5/26/2022
SinuSonic, a brand of Healthy Humming, LLC, is pleased to announce the presentation of the results from their study on "Double-blind, sham-controlled trial of a novel device for the treatment of viral upper respiratory tract infection."
-
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias
5/26/2022
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias.
-
Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests
5/26/2022
Meridian Bioscience, Inc. announced today that its inhibitor-tolerant qPCR master mixes are ideal for the development of fast, accurate and highly sensitive qPCR monkeypox virus (monkeypox) molecular diagnostic tests.